Clinical management of pregnant women with the risk of pre-eclampsia developing.

T. O. Loskutova


Hypertensive disorders in pregnancy remain important problem of modern obstetrics, their frequency being 2-8% with no tendency of decreasing. To identify pregnant women with high risk and to conduct preventive treatment is very important for the practitioner. The aim of the study was to develop and justify differential management of pregnants depending on the risk of preeclampsia. 131 pregnant women in I trimester were tested to determine the risk of hypertensive disorders. Prediction model allows to identify pregnant women with risk of hypertensive disorders according to the results of testing thrombophilia genes (presence of 455G → A polymorphism in the gene for fibrinogen β and 4G/5G in gene of plasminogen activator inhibitor - type 1), the level of antibodies to β2 glycoprotein-1, the level of D-dimer and the value of atherogenicity coefficient. Pregnant women with high risk of hypertensive disorders, received prophylactic treatment complex. This complex included antiplatelet therapy, correction of hyperho­mo­cysteinemia and hypercholesterolemia levels. Etio-pathogenic concept of prediction and prevention of pre-eclampsia associated with thrombophilia was proposed. The proposed scheme of preventive treatment allowed to normalize blood clotting parameters, lipid metabolism, to reduce the number of thrombophilia markers. The necessity of early and long-term administration of prophylactic complex was proved. This management prevents endothelial damage and deve­lopment of pathological range of pre-eclampsia. The results of prophylactic treatment were the reduction of preeclampsia cases by 6,5 times (p < 0.05), number of complicated deliveries by 3 times (p <0.05), number of preterm birth by 6,57 times (p <0.05), cases of growth retardation by 9,8 times (p = 0.003), increase of newborns’ weight by 1,24 times (p = 0.02).


pregnancy; pre-eclampsia; gene polymorphism; hemostasis; antiphospholipid antibodies; prognosis; probability; risk group; tactics

Full Text:



Loskutova ТО. [Effectiveness of prognosis of pre¬eclampsia in pregnancy]. Medichni perspectivy. 2014;XIX (1):101-7. Ukrainian 2. Baranov VS, Ivashchenko TE, Glotov AS. [De¬termination of genetic predisposition to certain diseases common in pregnancy: guidelines]. SPb.: «Iz-vo N-L». 2009;68. Russian. 3. [On approval of clinical protocols for obstetric and gynecological care: Order of 31.12.2004 № 676]. Mіnіsterstvo okhoroni zdorov’ya Ukraїni. K; 2004. Ukrainian. 4. Makatsariya AD, Bitsadze VO, Baymuradova SM, Perederyeva EB. [Prevention of recurrent pregnancy complications in terms of thrombophilia. Guide for Physicians]. M.: Triada Kh. 2008;152. Russian. 5. Turchin VN. [Probability theory and mathe¬matical statistics. Basic concepts, examples and tasks]. Dnipropetovsk: IMA-PRESS. 2012;576. Russian. 6. Gordon Guyatt H, Elie A, Crowther M. Anti¬throm¬botic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2)(suppl.):7S-47S. 7. Chappell LC, Seed P, Enye S. Clinical and geographical variation in prophylactic and therapeutic treatments for pre-eclampsia in the UK. BJOG. 2010;117(6):695-700. 8. Woodham PC, Boggess KA, Gardner MO. Rou¬tine antenatal thrombophilia screening in high-risk pregnancies: a decision analysis. Am. J. Perinatol. 2011;28(6):495-500. 9. Milne F, Redman C, Walker J. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of preeclampsia in the community. BMJ. 2005;330:576–80. 10. WHO recommendations for Prevention and treatment of pre-eclampsia and eclampsia. Geneva. Swit¬zerland: World Health Organization. 2011;38.

GOST Style Citations

1. Лоскутова Т.О. Ефективність прогнозування прееклампсії у вагітних / Т.О. Лоскутова // Медичні перспективи – 2014. – Т. XIX, №1. – С. 101-107. 2. Определение наследственной предраспо¬ложенности к некоторым частым заболеваниям при беременности: методические рекомендации / В.С. Ба¬ра¬нов, Т.Э. Иващенко, А.С. Глотов [и др.]; под ред. В.С. Баранова и Э.К. Айламазяна. – СПб.: «Из-во Н-Л», 2009. – 68 с. 3. Про затвердження клінічних протоколів з аку¬шерської та гінекологічної допомоги: наказ від 31.12.2004 р. / Міністерство охорони здоров’я Ук¬раїни. – К., 2004. – № 676. 4. Профилактика повторных осложнений бере¬мен¬ности в условиях тромбофилии. Руководство для врачей / А.Д Макацария, В.О. Бицадзе, С.М. Бай¬мурадова, Е.Б. Пе¬редеряева [и др.] - М.: Триада – Х, 2008.-152 с. 5. Турчин В.Н. Теория вероятностей и матема¬тическая статистика. Основные понятия, примеры и задачи / В.Н. Турчин. – Днепропетровск: ИМА-ПРЕСС, 2012. – 576 с. 6. Antithrombotic Therapy and Prevention of Throm¬bosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines / H. Gordon Guyatt, A. Elie, Crowther M [et al.] // Chest. – 2012. – Vol. 141, N 2, Suppl. – P. 7S-47S. 7. Clinical and geographical variation in prophy¬lactic and therapeutic treatments for pre-eclampsia in the UK / L.C. Chappell, P. Seed, S. Enye [et al.] // BJOG. – 2010. – Vol. 117, N 6. – P. 695-700. 8. Routine antenatal thrombophilia screening in high-risk pregnancies: a decision analysis / P.C. Woodham, K.A. Boggess, M.O. Gardner [et al.] // Am. J. Peri¬natol.– 2011. – Vol. 28, N 6. – Р. 495-500. 9. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre¬eclampsia in the community / F. Milne, C. Redman, J. Walker [et al.] // BMJ. – 2005. – Vol. 330. – P. 576–580. 10. WHO recommendations for Prevention and treat¬ment of pre-eclampsia and eclampsia – Geneva. Switzer¬land: World Health Organization, 2011. – 38 p.



M. M. Zelinka-Khobzey, K. V. Tarasenko
Bulletin of Problems Biology and Medicine  Vol: 1  Issue: 2  First page: 34  Year: 2019  
doi: 10.29254/2077-4214-2019-1-2-149-34-40


This work is licensed under a Creative Commons Attribution 4.0 International License